In the BioHarmony Drug Report Database
Sofosbuvir
Sovaldi (sofosbuvir) is a small molecule pharmaceutical. Sofosbuvir was first approved as Sovaldi on 2013-12-06. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Sovaldi’s patents are valid until 2030-12-11 (FDA).
Trade Name
|
Sovaldi |
|---|---|
Common Name
|
sofosbuvir |
ChEMBL ID
|
CHEMBL1259059 |
Indication
|
chronic hepatitis c, hepatitis c |
Drug Class
|
Phosphoro-derivatives; antivirals: RNA polymerase (NS5B) inhibitor |
Image (chem structure or protein)